embecta announces changes to Board of Directors

Core Points - Embecta Corp. announced the resignation of David J. Albritton from the Board of Directors due to personal reasons, effective immediately [1] - LTG (Ret.) David F. Melcher will not seek re-election at the 2026 annual stockholder meeting and will retire from the Board due to other commitments [1] - Both Albritton and Melcher have been Directors since the Board's inception in 2022 [1] Leadership Transition - Devdatt "Dev" Kurdikar, President and CEO, expressed gratitude for the contributions of both departing Directors, highlighting their leadership during the company's establishment [2] - Kurdikar noted the importance of Melcher's mentorship and leadership in navigating complex initiatives [2] - The Board plans to appoint Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director upon Melcher's departure [2] Company Overview - Embecta is transitioning from its initial phase to a focus on growth, with a commitment to prioritize the needs of customers, employees, and shareholders [2] - The company has a 100-year legacy in insulin delivery and aims to become a broad-based medical supplies company [3] - Embecta employs approximately 2,000 individuals globally, dedicated to improving lives through innovative solutions [3]